Qilu Pharmaceutical's Pomalidomide Capsules Approved as China's Second Domestic Version Amid 904% Sales Surge in the Market

Jun 03, 2024 20:31 CST Updated 20:31

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position. Authorization is required for the reprint of any article.

On June 3, according to the official website of NMPA,Qilu PharmaceuticalThePomalidomide CapsulesApproved for marketing. According to the data from PharmaCloudStatistics show that Zhengdatianqing's pomalidomide capsule was approved for marketing in November 2020, becoming the first generic version in China. This approval of Qilu Pharmaceutical is the second in China.

Screenshot source: NMPA

PomalidomideOriginal Research Drug byCelgene CorporationDevelopment, WorkAs a third-generation immunomodulatory agent, it is suitable for patients with multiple myeloma who have previously received at least two treatments, including lenalidomide and bortezomib, and have demonstrated disease progression or completed their last treatment within 60 days.

In the 2021 medical insurance negotiations, the pomalidomide capsules from Zhengda Tianqing Pharmaceutical Group were successfully included in the insurance, followed by a wave of sales growth.According to the data from PharmaCloud,Pomalidomide CapsulesIn 2022, the sales revenue in the Chinese hospital market exceeded 80 million yuan, with a year-on-year increase of 904.85%. Entering 2023,(As of Q3)Its market performance remains strong,Pomalidomide CapsulesSales in hospitals across China have approached 100 million yuan, demonstrating strong market potential and a trend of continuous growth.

Screenshot source:PharmCube National Hospital Sales Database

Previously,Pomalidomide CapsulesOnly Chia Tai Tianqing Pharmaceutical has been approved and passed the evaluation, making it an exclusive product. Chia Tai Tianqing obtained China's first generic approval and was the first to pass the evaluation in 2020. This time, Qilu Pharmaceutical is the second pharmaceutical company in China to gain approval and pass the evaluation.

Screenshot source:PharmCube China Drug Approval Database

In terms of generic drug layout, Yangtze River Pharmaceutical in China has submittedPomalidomide CapsulesTheGeneric application is still under review.

Screenshot source:PharmCube China Drug Evaluation Database

In addition to this approvalPomalidomide Capsules, this year(As of June 3)Qilu Pharmaceutical also hasCarvedilol Tablets, Fluorouracil Injection, Doxorubicin Hydrochloride Liposome Injection, Cefaclor CapsulesThirteen varieties passed the evaluation, includingCarvedilol Tablets, Cefpodoxime Proxetil Tablets, Bendamustine Hydrochloride Injection Concentrate, Eltrombopag Ethanolamine TabletsFour varieties are the first to pass the evaluation.

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Reply to the keyword "Report", access dozens of exclusive reports produced by Yaorong Cloud
Reply to the keyword "CSCO", Obtain 2023 CSCO Guidelines
Reply to the keyword "ASCO", Obtain 2023 ASCO Abstract by Cancer Type
Reply to the keyword "First Generic in 2023", Obtain the list of first generic drugs approved in 2023
Reply to the keyword "Medical Insurance", obtain the 2022 medical insurance directory

Contact us to experience more professional services from PharmaCloud.

MeetingDiscussion

CombinedMade

GardenDistrict

TakeService

Database

Consultation

Customization

Service

Media

Cooperation

ClickReadRead the Original Text, apply for a free trial of PharmaSpring Enterprise Edition!